Merck announced that the FDA has approved Janumet XR (sitagliptin/metformin HCl extended-release tablets) for the treatment of type 2 diabetes. Janumet XR is indicated as an adjunct to diet and ...

Whitehouse Station, NJ - Merck announced on February 2, 2012 that the US Food and Drug Administration (FDA) has approved Janumet XR (sitagliptin and extended-release metformin hydrochloride) tablets ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved JANUMET ® XR ...

JANUMET XR is indicated, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin extended-release is ...

The new formulation, meant to be used as an adjunct to diet and exercise to improve glycemic control, combines sitagliptin (the active component of Januvia [Merck]), with extended-release metformin.

Sitagliptin, metformin (as HCl) ext-rel; 50mg/500mg, 50mg/1000mg, 100mg/1000mg; tabs. Individualize. Swallow whole. Take once daily with a meal, preferably in the evening. Not currently treated with ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. SITAGLIPTIN/METFORMIN XR MYLAN contains the active ingredients ...

AHMEDABAD, India, Jan. 7, 2025 /PRNewswire/ -- Zydus Lifesciences Ltd. (including its subsidiaries/affiliates, hereafter referred to as 'Zydus'), a global innovation ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. JANUMET XR contains the active ingredients sitagliptin (as phosphate ...